September 19, 2017 – Raleigh, NC

MAA Laboratories has been awarded an NIH Phase I Small Business Innovation Research (SBIR) grant. Awarded via the National Cancer Institute, an institute of the NIH, the SBIR grant will provide non-dilutive funding to MAA Laboratories to develop a novel formulation of an anti-leukemia drug product, which currently has significant deficiencies related to dosing and bioavailability.The goal of the project is to use MAA’s proprietary NanoCont^TM technology to create an anti-leukemia drug product with markedly improve performance, which will provide an improved therapeutic option for patients with leukemia. 

About MAA Laboratories Inc.
MAA Laboratories Inc. is a specialty pharmaceutical company located in the Research Triangle Park region of North Carolina. MAA has developed the NanoCont^TM drug development platform as a broadly applicable solution for addressing a variety of drug delivery and development challenges. Our company is dedicated to using the NanoCont^TM technology to create advanced medicines that improve patients’ lives by addressing unmet clinical needs in a variety of therapeutic areas, including oncology, neurological, and cardiovascular diseases.

The NanoCont^TM drug development platform
MAA Laboratories’ NanoCont^TM technology is a broadly applicable drug development solution for improving the clinical performance of poorly soluble pharmaceuticals. Aspects of drug performance that can be improved by the NanonCont^TM technology include: increased therapeutic efficiency, enhanced targeted drug delivery, elimination of food effects, increased oral bioavailability, reduced intra- and inter-patient variability, and/or mitigated undesirable side effects. This technology can be used to reformulate marketed products in a manner that resolves known drug performance liabilities and creates new intellectual property protection. For investigational compounds, the NanoCont^TM technology can be used to overcome hurdles related to low solubility and poor bioavailability to ensure consistent dosing and facilitating the development of promising pipeline compounds.

Contact MAA Laboratories
For inquiries related to product licensing and development partnerships, please contact our business development team at BD@maalaboratories.com.

For press and other inquiries, please contact:

Corporate Office
MAA Laboratories, Inc.
310 S. Harrington Street
Raleigh, NC 27601
Email: info@maalaboratories.com
Phone: 919.271.7868